NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Sees Significant Increase in Short Interest

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) saw a significant increase in short interest in January. As of January 15th, there was short interest totaling 3,527,843 shares, an increase of 92.7% from the December 31st total of 1,831,090 shares. Based on an average daily trading volume, of 2,710,433 shares, the short-interest ratio is currently 1.3 days. Approximately 14.7% of the company’s stock are sold short. Approximately 14.7% of the company’s stock are sold short. Based on an average daily trading volume, of 2,710,433 shares, the short-interest ratio is currently 1.3 days.

Institutional Investors Weigh In On NRx Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in NRXP. Anson Funds Management LP boosted its position in NRx Pharmaceuticals by 26.2% in the 3rd quarter. Anson Funds Management LP now owns 2,025,104 shares of the company’s stock valued at $6,683,000 after buying an additional 420,129 shares during the last quarter. Vanguard Group Inc. grew its stake in NRx Pharmaceuticals by 18.3% during the 3rd quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after purchasing an additional 82,781 shares in the last quarter. AdvisorShares Investments LLC raised its position in shares of NRx Pharmaceuticals by 29.7% in the 3rd quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock valued at $1,129,000 after purchasing an additional 78,339 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of NRx Pharmaceuticals by 27.9% during the 2nd quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock valued at $562,000 after buying an additional 37,598 shares during the last quarter. Finally, Two Sigma Investments LP raised its stake in shares of NRx Pharmaceuticals by 66.4% in the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock valued at $173,000 after purchasing an additional 20,880 shares in the last quarter. 4.27% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on NRXP. BTIG Research reissued a “buy” rating and issued a $25.00 target price on shares of NRx Pharmaceuticals in a research report on Thursday, January 15th. Ascendiant Capital Markets restated a “buy” rating and issued a $48.00 target price (up previously from $47.00) on shares of NRx Pharmaceuticals in a research note on Friday, January 2nd. D. Boral Capital reissued a “buy” rating and set a $34.00 price target on shares of NRx Pharmaceuticals in a report on Monday, January 5th. Wall Street Zen raised NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, November 23rd. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of NRx Pharmaceuticals in a research report on Monday, December 29th. Four investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $36.75.

NRx Pharmaceuticals Stock Performance

Shares of NASDAQ NRXP traded down $0.02 during midday trading on Friday, reaching $2.10. 379,991 shares of the stock were exchanged, compared to its average volume of 1,785,069. The stock has a 50 day moving average price of $2.31 and a 200-day moving average price of $2.66. NRx Pharmaceuticals has a 52-week low of $1.58 and a 52-week high of $3.84.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.07). The business had revenue of $0.24 million during the quarter, compared to analysts’ expectations of $6.83 million. On average, equities analysts anticipate that NRx Pharmaceuticals will post -1.75 earnings per share for the current year.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.